SARCOPEDIA - Sarcopenia Diagnostics in Aging Medicine

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-07-11

Study Completion Date

2024-10-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Musculoskeletal aging is one of the major responsibilities and challenges for public health. In particular, sarcopenia correlates with an increased risk of falls and increased morbidity and mortality. With regard to screening for sarcopenia, the guidelines of the European Working Group on Sarcopenia in Older People (EWGSOP2) refer to algorithmic case finding, diagnosis, and quantification of the severity of sarcopenia in clinical. While functional measurements are more difficult to standardize and associated with higher variability, Dual-energy X-ray absorptiometry (DXA) is considered a highly accurate method, even referred to as the "gold standard" to determine muscle mass in the scientific literature. Nevertheless, DXA, which is routinely used, shows inconsistent correlation with functional decline in muscle strength. Another method of muscle quantification is bioelectrical impedance analysis (BIA), a simple, portable instrument that is more readily available and applicable due to its lower cost. However, it tends to overestimate muscle mass and is also more susceptible to a person's hydration status. Because of these difficulties, recent research has focused on the potential of using shear wave elastography. This method indirectly serves to quantify the rapid type II muscle fibers in order to make statements about the muscle quality because an age-related decrease in type II muscle fibers is associated with a more frequent fall frequency.

First, the investigators will define three different categories according to the EWGSOP 2 guidelines based on the muscle strength (grip strength, assessed by pneumatic hand dynamometer) and muscle mass (Appendicular skeletal muscle mass, assessed by BIA): "No Sarcopenia", "Probable Sarcopenia" and "Confirmed Sarcopenia". Within these categories, the Investigators would like to establish a multivariate data analysis of different functional measurements with quantitative imaging results. This exploratory trial design is intended to improve understanding within the three categories and to test proxy measurements of different patients who are ruled out for common routine measurements due to, for example, cognitive impairment or pre-existing rheumatic disease. This is essential to consider the heterogeneity of the aging society proportionally.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Diagnostic Evaluation of Sarcopenia in Elderly Patients

NCT04451005

Sarcopenia

COMPLETED

Prevalence of Sarcopenia in Geriatric Patients

NCT04124575

Sarcopenia

COMPLETED

Sarcopenia in Acute Care Patients: Protocol for Sarcopenia 9+

NCT03917667

Sarcopenia

COMPLETED

Case Control in Sarcopenia Among Elderly Type 2 Diabetic Patients

NCT07244601

Sarcopenia

NOT_YET_RECRUITING

Sarcopenia Screening Application for Sarcopenia

NCT07041996

Geriatrics Rehabilitation

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Once written informed consent is available, the following data are extracted from the patient's medical records: age and gender, number of medications and number of pre-existing chronic conditions, statin therapy (binary evaluation yes/ no), the laboratory values for CRP, prealbumin, cholinesterase, GFR and CK, and results from geriatric assessment routinely performed by a physiotherapist at admission or a resident physician: Mini Mental State Exam (MMSE), Clock-drawing test (CDT), Geriatric depression scale (GDS), Functional independence measure at admission (FIM) assessed by nurses or physiotherapist. Hand grip strength (HGS), Timed up and go Test (TUG) and Gait speed at admission assessed by physiotherapists; Nutritional risk screening (NRS) assessed by a nutritionist.

To complete baseline data, calf and mid-arm circumference will be measured. Meanwhile, the frailty of the participant is estimated by using the CFS.

For evaluation of muscle mass, body impedance analysis (BIA) is performed in all included patients using a BIVA 101® (Akern, SMT medical GmbH, Würzburg, Germany) within the first 6 days of hospitalization. To conduct this measurement, the patients lie in supine position with extremities stretched, not touching their core and not moving during the measurement. The measurement itself takes only a few seconds. Altogether, the measurements including the preparation phase will be performed within 10 to 15 minutes. As a potential bias, the hydration status of a patient can impair reliability of BIA results. Therefore, all measurements will take part at least 2 hours after the last meal in order to minimize possible fluctuations. If a patient suffers from an altered hydration status at admission (either clinically dehydrated or volume overloaded), the patient will be re-evaluated three days later and BIA measurement will be done if the patient is euvolemic at that time. Concerning those patients receiving continuous enteral feeding, BIA measurement will be performed only if \<150 ml/h were delivered in the preceding 2 hours.

For further assessment of muscle mass, non-invasive DXA provides the total body Skeletal Muscle Mass (SMM) and the Appendicular Skeletal Muscle Mass (ASM). For these examinations, the patient cannot stay at her/ his room and will be transferred to an examination room. There an experienced physician will be present if needed for medical assistance before, during or after measurements. The device used for this study is the iDXA densitometer (GE Healthcare, Madison, WI, USA). Here, the study participant moves to an examination couch. The instrument, which is located opposite the examination couch, has an open design and can be viewed from all sides. A narrow scanner runs over the body at a distance of about 20 cm. The examination itself takes about 5 minutes while the patient remains relaxed and calm, breathing normally. In principle, muscle mass is correlated with body size, i.e. persons with a larger body size usually have a larger muscle mass. Therefore, when quantifying muscle mass, the absolute level of SMM or ASM can be adjusted for body size in several ways, namely by using height squared (ASM/height2), weight (ASM/weight), or body mass index (ASM/BMI), all of which are included in the assessment. As a definition of sarcopenia, cut-off points from EWGSOP2 will be used. All precision scans are performed by the same radiologic technologist under the supervision of the project manager.

A subsequent ultrasound examination (Philips PureWave EPIQ 5G, Amsterdam, Netherlands) will be used to detect the elasticity via elastography of two muscles in defined positions. The measurements positions are the Musculus (M.) quadriceps femoris in a supine position on an examination couch and the M. biceps brachii in an elbow flexed position at 90° with the forearm rested on the body. The probe will be placed on top of the skin with a minimal load ensuring no external pressure could affect the measurements. The elastography will be recorded in kilopascals (kPa). The examination, which takes about 5 minutes is also completely painless, and will be performed by the project leader.

The CST is then performed under the supervision and guidance of the examining physician. This clinical test is also used to assess mobility and is estimated to take approximately 3 minutes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcopenia Muscle Weakness Frailty

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

No Sarcopenia (Control Group)

healthy participants

Group Type OTHER

dual x-ray absorptiometry, body impedance analysis, muscle strength measurements, ultrasound

Intervention Type DIAGNOSTIC_TEST

Results from the routine geriatric assessment:

* Mini Mental State Exam (MMSE)
* Clock-drawing test (CDT)
* Geriatric depression scale (GDS)
* Functional independence measure (FIM) at admission
* Timed up and go Test (TUG)
* Gait speed
* Hand grip strength (HGS)
* Nutritional risk screening (NRS)

Additional measurements:

* Chair-stand-test
* Clinical frailty scale (CFS)
* Calf circumference and mid-arm circumference
* Body impedance analysis (BIA)
* US
* DXA

Sarcopenia is probable

Low muscle strength (in accordance with the guidlines of "The European Working Group on Sarcopenia in Older People 2" (EWGSOP2))

Group Type OTHER

dual x-ray absorptiometry, body impedance analysis, muscle strength measurements, ultrasound

Intervention Type DIAGNOSTIC_TEST

Results from the routine geriatric assessment:

* Mini Mental State Exam (MMSE)
* Clock-drawing test (CDT)
* Geriatric depression scale (GDS)
* Functional independence measure (FIM) at admission
* Timed up and go Test (TUG)
* Gait speed
* Hand grip strength (HGS)
* Nutritional risk screening (NRS)

Additional measurements:

* Chair-stand-test
* Clinical frailty scale (CFS)
* Calf circumference and mid-arm circumference
* Body impedance analysis (BIA)
* US
* DXA

Sarcopenia is confirmed

Low muscle strength + low muscle quantity (in accordance with the guidlines of "The European Working Group on Sarcopenia in Older People 2" (EWGSOP2))

Group Type OTHER

dual x-ray absorptiometry, body impedance analysis, muscle strength measurements, ultrasound

Intervention Type DIAGNOSTIC_TEST

Results from the routine geriatric assessment:

* Mini Mental State Exam (MMSE)
* Clock-drawing test (CDT)
* Geriatric depression scale (GDS)
* Functional independence measure (FIM) at admission
* Timed up and go Test (TUG)
* Gait speed
* Hand grip strength (HGS)
* Nutritional risk screening (NRS)

Additional measurements:

* Chair-stand-test
* Clinical frailty scale (CFS)
* Calf circumference and mid-arm circumference
* Body impedance analysis (BIA)
* US
* DXA

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

dual x-ray absorptiometry, body impedance analysis, muscle strength measurements, ultrasound

Results from the routine geriatric assessment:

* Mini Mental State Exam (MMSE)
* Clock-drawing test (CDT)
* Geriatric depression scale (GDS)
* Functional independence measure (FIM) at admission
* Timed up and go Test (TUG)
* Gait speed
* Hand grip strength (HGS)
* Nutritional risk screening (NRS)

Additional measurements:

* Chair-stand-test
* Clinical frailty scale (CFS)
* Calf circumference and mid-arm circumference
* Body impedance analysis (BIA)
* US
* DXA

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

The investigators aim to include patients ≥ 65 years old newly admitted for study eligibility at the UAFP.

Exclusion Criteria

* Lack of informed written consent
* Implanted defibrillation device
* Implanted pacemaker
* Acute sepsis or severe volume overload
* Life expectancy of \< 3 months according to treating doctor
* bedridden
* Plasters or bandages that cannot be removed from the feet or hands
* Isolated patients (contact and aerosol)
* Measurement is not possible due to organizational reasons
* Inability to follow the procedures, e.g. due to language problems, psychological disorders

Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes